Our research demonstrated that compared with that of the control group, the expression of IL-1β was evidently increased in activated SGCs (DM group), while there was a noteworthy reduction in the expression after either P2Y14 shRNA or naringin treatment. The gene discussed is P2RY14; the disease is diabetes mellitus.